Healthcare / Medical DevicesMilan
$0.71
-0.00 (-0.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-351310.00 · quality 27.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
35.5x
↑EV/EBITDA
4.4x
↓ROE
3.9%
↑Gross Margin
46.6%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.5%
FCF CAGR
—
FCF margin
-4.6%
FCF / Net income
-2.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.6M · net income $170527.0 · FCF $-351310.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.6M | $7.6M | $6.6M | $7.2M | $5.5M |
| Net Income | $170527.00 | $170527.00 | $335767.00 | $190569.00 | $167000.00 |
| EBITDA | $819828.00 | $819828.00 | $814884.00 | $813015.00 | $659000.00 |
| EPS | — | — | — | 0.03 | 0.02 |
| Gross Margin | 46.6% | 46.6% | 40.0% | 37.4% | 40.4% |
| Operating Margin | 3.7% | 3.7% | 8.6% | 5.1% | 6.1% |
| Net Margin | 2.2% | 2.2% | 5.1% | 2.6% | 3.0% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.09 | 0.14 | 0.30 |
| Current Ratio | 1.62 | 1.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-351310.00 | $-351310.00 | $-610363.00 | $954319.00 | $-1.1M |
| Returns | |||||
| ROE | 3.9% | 3.9% | 8.0% | 8.0% | 7.6% |
| Valuation | |||||
| P/E | 35.50 | 35.50 | — | — | — |
| EV/EBITDA | 4.35 | 4.35 | 3.07 | — | — |
| P/B | 1.24 | 1.24 | 1.12 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 14.6% | 14.6% | -8.2% | 31.7% | — |
| EPS Growth | — | — | — | 14.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+23.1%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
+23.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.